

Genomtec to issue shares to Shareholder - 5HT Family Foundation

The company will obtain approximately PLN 11 million from the issue to support the commercialization of projects

The shareholders of Genomtec SA, a leading molecular diagnostics company headquartered in Wrocław (WSE ticker: GMT), at the Extraordinary General Meeting on 12 March 2025 voted on a resolution to increase the Company's share capital by issuing 1,542,556 new ordinary bearer shares of series P, with the entire exclusion of the subscription rights of the existing shareholders. Genomtec will gain approximately PLN 11 million (gross) from the share issue, which will secure the Company's financial position for the coming months and will allow for further development of projects and efficient implementation of the M&A process.

"We are pleased that the Shareholders at the EGM supported the resolution on the issue of new shares. The issue directed to 5HT actually crowns the process in which this entity conducted a share offer, as a result of which a number of investors joined our shareholding. The funds obtained from the share issue will reach Genomtec within a few weeks and will secure our financial needs for the key period in which we are conducting advanced negotiations with potential partners in the commercialization of our projects. The talks to date have resulted in the signing of confidentiality agreements with partners from Europe and North America. At the same time, we are observing growing interest from Asian markets. Therefore, in parallel with Clairfield's work focused on the sale of Genomtec ID, we have decided to establish additional cooperation with the renowned transaction advisor Lynx Financial based in Shanghai, which will support the process of preparing and selling the OncoSNAAT project on Asian markets." - says Miron Tokarski, President of the Management Board of Genomtec SA

Genomtec SA concluded an investment agreement with the Company's Shareholder - 5HT Fundacja Rodzinna on February 12 this year. According to the agreement, the Shareholder sold 1,342,556 existing and admitted to trading shares of the Company at a price of PLN 7 per share, which were acquired by a total of 13 investors. Then, in accordance with the resolution of the EGM, the Company will be obliged to offer 1,542,556 Shares of the new issue for the Shareholder to take up at a unit issue price equal to the price of shares sold in ABB.

The company's flagship project is the Genomtec ID mobile diagnostic system. The platform consists of an analyzer and a reaction card with integrated genetic tests. The second OncoSNAAT project involves developing technology for detecting mutations in the oncological area, which indicate the most effective therapy. At the end of January this year, Genomtec filed a patent application in the OncoSNAAT oncological project for an invention in the area of diagnostics of single-nucleotide genetic changes. This is the second patent application filed by the company in the area of oncological diagnostics.

Legal disclaimer

This publication is for informational purposes only and does not serve in any way, directly or indirectly, to promote the offer of the Company's shares conducted by the shareholder and is not promotional material or advertising prepared or published by the Company for the purpose of promoting the Company's shares or their subscription or encouraging, directly or indirectly, to acquire them. This publication does not constitute a prospectus or any other memorandum or information or offering document. In connection with the matters that are the subject of this publication, a prospectus will not be made available and the preparation of such a prospectus is not required. This publication does not contain or constitute an offer to sell or subscribe for securities or an invitation to submit an offer to acquire securities or an encouragement/recommendation to acquire securities, including an investment recommendation within the meaning of the relevant regulations and under no circumstances does it constitute a basis for making a decision to acquire the Company's securities. This publication and the information contained herein are restricted and not intended for publication, announcement, distribution or transmission, directly or indirectly, in whole or in part, in or into the United States of America, Australia, Canada, South Africa, Japan or any other country where such publication, announcement, distribution or transmission would be unlawful.

About Genomtec:

Genomtec is a MedTech company specializing in developing advanced technologies in the field of genetic diagnostics. The Company's flagship project is the Genomtec ID mobile diagnostic system. The system allows for fast and precise molecular analysis outside the laboratory environment without the need to engage qualified laboratory personnel. The solution uses microfluidic technology and proprietary, patented, isothermal SNAAT® technology. Genomtec technology is protected by 12 patents, including in Europe, the USA and Japan, and the Company has 35 patent applications pending.

The Company has EU CE-IVD certification for the Genomtec ID RP5-PLEX diagnostic panel, which simultaneously detects the presence of the most common respiratory tract infections

The Company's headquarters are located in Wrocław, Poland. Genomtec also has a branch in Great Britain, where part of the international research and engineering team is located.

More information is available on the Company's website: www.genomtec.com

Media contact:

Michał Wierzychowski

Tel.: +48 531 613 067

michal.wierzychowski@ccgroup.pl

Contact for investors:

Agata Dzieciołowska

Tel.: +48 606 205 119

agata.dzieciolowska@ccgroup.pl